By eCliniqua Staff 

 

May 15, 2013 | Certara and Veristat have formed an alliance to offer pharmacokinetic (PK) analysis, PK /pharmacodynamic (PD) modeling, population PK modeling, trial simulation, clinical biostatistics, medical writing, data management, clinical monitoring, safety management, and project management to their clients. 

 

The companies hope the combined services will help streamline the drug discovery, development and trial planning processes by improving the efficiency of data collection and analysis and enabling clients to procure value-added services through their existing vendor relationship. 

 

"Certara partnered with Veristat because our clients are increasing their collaboration with contract research organizations that specialize in certain areas such as PKPD and PBPK modeling and simulation,” Daniel Weiner, CTO and head of Certara’s scientific consulting services, told eCliniqua. “Veristat’s strengths in biostats and data management are highly complementary to Certara’s expertise that was formed from the integration of Pharsight and Simcyp. Clients want their software, vendor relationships, and outsourcing strategies to support efficient trial execution and analysis. This partnership will deliver improvements in cost, time, and quality of development results."

 

“We look forward to offering Certara’s capabilities to our clients,” said Patrick Flanagan, chief business officer of Veristat in a statement. “Their Pharsight Consulting Services team is a world-class organization in the modeling and simulation of drugs and diseases. By combining our core services with their insight and experience, Veristat broadens our delivery platform and is able to more immediately respond to our clients’ outsourcing needs. The benefit to our clients is greater overall efficiency, impact and probability of success for their clinical trial programs.”